High Point R&D Tax Credit Benefits for Businesses

R&D Tax Credits for High Point, North Carolina Businesses

High Point, North Carolina, is known for industries such as manufacturing, healthcare, education, retail, and furniture. Top companies in the city include High Point University, a leading educational institution; High Point Regional Health, a major healthcare provider; Thomas Built Buses, a significant manufacturing employer; Walmart, a key player in the retail sector; and the High Point Market, a prominent furniture trade show. The R&D Tax Credit can help these industries save on taxes by encouraging innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6255 Towncenter Drive, Clemmons, North Carolina is less than 30 miles away from High Point and provides R&D tax credit consulting and advisory services to High Point and the surrounding areas such as: Greensboro, Winston-Salem, Fayetteville, Cary and Burlington.

If you have any questions or need further assistance, please call or email our local North Carolina Partner on (984) 480-4601.
Feel free to book a quick teleconference with one of our North Carolina R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

High Point, North Carolina Patent of the Year – 2024/2025

VTV Therapeutics LLC has been awarded the 2024/2025 Patent of the Year for its groundbreaking work in pharmaceutical chemistry. Their invention, detailed in U.S. Patent No. 11883383, titled ‘Pharmaceutically acceptable salts of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine’, introduces a novel class of compounds aimed at treating diseases mediated by the receptor for advanced glycation end products (RAGE).

This innovation focuses on developing stable, pharmaceutically acceptable salts of a specific compound known to inhibit RAGE. By creating these salts, vTv Therapeutics enhances the compound’s solubility and bioavailability, potentially improving its effectiveness as a therapeutic agent.

RAGE is implicated in various chronic conditions, including diabetes-related complications, Alzheimer’s disease, and certain cancers. By targeting this receptor, the new compounds could offer a versatile approach to managing these diseases.

The patent outlines methods for synthesizing these salts and demonstrates their potential in preclinical models. This advancement not only represents a significant step in drug development but also opens avenues for future research into RAGE-related therapies.

With this patent, vTv Therapeutics solidifies its position at the forefront of pharmaceutical innovation, offering hope for more effective treatments for complex diseases.